Anchored by: Jeremy Forman - VP, Research & Development AI, Data, & Analytics, Pfizer
The impact of AI on the research and development (R&D) landscape is profound and multifaceted, reshaping traditional methodologies and accelerating scientific progress across diverse industries. AI algorithms, powered by vast amounts of data and computational power, have revolutionized R&D processes by enabling rapid analysis, prediction, and optimization.
By automating tedious tasks, streamlining decision-making processes, and uncovering patterns in complex datasets, AI empowers researchers to explore novel hypotheses, identify promising leads, and bring transformative products and solutions to market faster than ever before.
Join this master class where we will be discussing, how AI will impact the R&D landscape, in particular:
- How has the integration of AI technologies impacted the efficiency and efficacy of R&D processes across various industries, and what are the key factors influencing the successful adoption and implementation of AI-driven approaches?
- What are the ethical considerations surrounding the use of AI in R&D, particularly regarding data privacy, bias mitigation, and ensuring responsible deployment of AI-driven technologies?
- In what ways can organizations effectively leverage AI to enhance collaboration and knowledge sharing among interdisciplinary teams within the R&D landscape, fostering a culture of innovation and accelerating the pace of discovery?
Current Participants:
- Jo Peddhinti - Director, Insights & Advisory, HLTH
- Jeremy Forman - Vice President, Research & Development AI, Data, & Analytics, PFIZER
- Danny Bosch - Associate Director of Business Development and Commercial, IMPERIAL COLLEGE HEALTH PARTNERS
- Zina Manji - Founder/Principal, Regulatory Strategist, INNOPATHWAYZ, LLC
- Chris Cera - CEO, ARCWEB TECHNOLOGIES
- Anna-Maria Heidinger - Head of Digital Innovation Hub, DAIICHI SANKYO EUROPE
- Julie Fishman - Executive Director, Global Commercial Head, Rx+ Business Accelerator, ASTELLAS PHARMA
- Taiba Quraishi - Alexion Innovation Accelerator- Lead, ALEXION PHARMACEUTICALS
- Vincent Lepreux - Investment Principal, DEBIOPHARM INNOVATION FUND
- Alette Brinth - Director of Digital Innovation, NOVARTIS
- Simon Bock - Market Access Manager & Digital Strategist, TIEFENBACHER PHARMAECEUTICALS
- Weronika Michaluk - MedTech & SaMD Practice Lead, HTD HEALTH
- Marc Phippen - Innovation Strategy Director, NOVARTIS
